尽管亏损，MacroGenics 的盈利预期仍超出预期，凭借高于预期的收入推动股价上涨。 MacroGenics beat earnings estimates despite a loss, boosting stock on higher-than-expected revenue.

宏观公司(MGNX)星期一报告第二季度收入,每股亏损22美元,估计亏损20美元,收入为4 123万美元,超过2 781万美元的预测。 MacroGenics (MGNX) reported second-quarter earnings on Monday, posting a loss of $0.22 per share, beating estimates by $0.20, and generating $41.23 million in revenue, surpassing forecasts of $27.81 million. 尽管利指标呈负面, 但周二的股价仍升至2.96美元, 交易量超过平均水平的两倍. Despite negative profitability metrics, the results lifted the stock to $2.96 on Tuesday, with trading volume more than double average. 临床阶段生物制药公司侧重于癌症和自生免疫疾病的单克隆抗体疗法,继续开发先进的抗体技术。 The clinical-stage biopharmaceutical company, focused on monoclonal antibody therapies for cancer and autoimmune diseases, continues developing advanced antibody technologies. 分析员保持好坏参半的前景,一致的“稳住”评级和平均价格目标为3.80美元。 Analysts maintain a mixed outlook with a consensus "Hold" rating and an average price target of $3.80. 机构投资者持有96.89%的股份。 Institutional investors own 96.89% of shares.